PHOENIX SECRETOMICS DR5: total 630 amino acids; 68986 Da; Molecular function: Megakaryocyte-potentiating factor: Secreted |
||
10 20 30 40 50 60
MALPTARPLL GSCGTPALGS LLFLLFSLGW VQPSRTLAGE TGQEAAPLDG VLANPPNISS
70 80 90 100 110 120
LSPRQLLGFP CAEVSGLSTE RVRELAVALA QKNVKLSTEQ LRCLAHRLSE PPEDLDALPL
130 140 150 160 170 180
DLLLFLNPDA FSGPQACTRF FSRITKANVD LLPRGAPERQ RLLPAALACW GVRGSLLSEA
190 200 210 220 230 240
DVRALGGLAC DLPGRFVAES AEVLLPRLVS CPGPLDQDQQ EAARAALQGG GPPYGPPSTW
250 260 270 280 290 300
SVSTMDALRG LLPVLGQPII RSIPQGIVAA WRQRSSRDPS WRQPERTILR PRFRREVEKT
310 320 330 340 350 360
ACPSGKKARE IDESLIFYKK WELEACVDAA LLATQMDRVN AIPFTYEQLD VLKHKLDELY
370 380 390 400 410 420
PQGYPESVIQ HLGYLFLKMS PEDIRKWNVT SLETLKALLE VNKGHEMSPQ APRRPLPQVA
430 440 450 460 470 480
TLIDRFVKGR GQLDKDTLDT LTAFYPGYLC SLSPEELSSV PPSSIWAVRP QDLDTCDPRQ
490 500 510 520 530 540
LDVLYPKARL AFQNMNGSEY FVKIQSFLGG APTEDLKALS QQNVSMDLAT FMKLRTDAVL
550 560 570 580 590 600
PLTVAEVQKL LGPHVEGLKA EERHRPVRDW ILRQRQDDLD TLGLGLQGGI PNGYLVLDLS
610 620 630
MQEALSGTPC LLGPGPVLTV LALLLASTLA |
||
 |
||
| Formalin-fixed, paraffin-embedded human mesothelioma stained by Mesothelin monoclonal antibody | ||
 |
||
| In situ hybridization for mesothelin mRNA transcript using riboprobes. Argani P., et al. Clinical Cancer Research Vol. 7, 3862-3868, December 2001 | ||
 |
||
| Immunolabeling for mesothelin protein. There is strong labeling of the neoplastic epithelium and a complete absence of labeling in the nonneoplastic epithelium and stroma (A–C). Note the luminal accentuation of mesothelin labeling in C and D. | ||
Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin E via Activation of Signal Transducer and Activator of Transcription Protein 3 |
||
| Mesothelin (MSLN) is a cell surface glycoprotein that is overexpressed in human pancreatic cancer. Although its value as a tumor marker for diagnosis and prognosis and as a preferred target of immunointervention has been evaluated, there is little information on the growth advantage of MSLN on tumor cells. In this study, we examined the effect of MSLN on pancreatic cancer cell proliferation, cell cycle progression, expression of cell cycle regulatory proteins, and signal transduction pathways in two pancreatic cancer cell lines, MIA-MSLN (overexpressing MSLN in MIA PaCa-2 cells) and BxPC-siMSLN (silencing MSLN in BxPC-3 cells). Increased cyclin E and cyclin-dependent kinase 2 expression found in MIA-MSLN cells correlated with significantly increased cell proliferation and faster cell cycle progression compared with control cells. BxPC-siMSLN cells showed slower proliferation and slower entry into the S phase than control cells. Signal transducer and activator of transcription protein 3 (Stat3) was constitutively activated in MIA-MSLN cells, but not in control cells. Inhibition of Stat3 activation in MIA-MSLN cells by the Janus-activated kinase–selective inhibitor tyrphostin AG490 was followed by a marked decrease in proliferation of the cells. Small interfering RNA against Stat3 significantly reduced the MIA-MSLN cell cycle progression with a concomitant decrease in cyclin E expression. Our data indicate that overexpression of MSLN in pancreatic cancer cells leads to constitutive activation of the transcription factor Stat3, which results in enhanced expression of cyclin E and cyclin E/cyclin-dependent kinase 2 complex formation as well as increased G1-S transition. (Mol Cancer Res 2008;6(11):1755–65) |
| Antibody Name | Application | Specices | Host | Catalog No.: | Size |
Price |
| Mesothelin Monoclonal Antibody | IHC | h | mouse | PS001-39-MAG-01 | 7 ml |
400 |
| Mesothelin Monoclonal Antibody | IHC | h | mouse | PS001-39-MAG-02 | 50 ug |
300 |